| Name: | Abiraterone-beta-D-Glucuronide |
| Catalogue No. | VL830048 |
| CAS No. | N/A |
| Molecular Formula | C30H39NO7 |
| Molecular Weight | 525.65 |
| Status | Under Development |
| IUPAC Name | (2S,4R,5R,6R)-6-(((3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid |
| Description | Abiraterone-beta-D-Glucuronide(CAS No: N/A) or (2S,4R,5R,6R)-6-(((3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid,it is inhibits CYP17A1 in a selective and irreversible manner and is used in the treatment of prostate cancer |
| References | Thakur, Abhimanyu, et al. “Abiraterone Acetate in the Treatment of Prostate Cancer.” Biomedicine & Pharmacotherapy, vol. 101, May 2018, pp. 211–218, 10.1016/j.biopha.2018.02.067. |
